by Sara M. Nolte | Dec 19, 2024
I’m excited to be sharing some new Canadian cancer immunotherapy developments! We’ve already seen some great stuff with CAR T cells and checkpoint inhibitors. But the strength of these therapies is also their downfall: their targets make them highly specific and...
by Medicine by Design | Apr 15, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people of Medicine by Design.” Some minor edits...
by Stacey Johnson | Mar 29, 2024
Dr. Michel Sadelain, the “inventor of T cells” and a graduate of the University of Alberta, has won the 2024 Breakthrough Prize in life sciences. After completing his medical degree at the University of Paris, Dr. Sadelain earned his PhD in immunology at the...
by Sara M. Nolte | Sep 21, 2022
We (or maybe it’s just me) talk about cancer immunotherapy around here A LOT. It’s hard not to when there are so many new advancements in this field of cancer research! I thought it was time to provide a guide to cancer immunotherapy, highlighting some of the more...
by Sara M. Nolte | May 28, 2020
Cancer immunotherapy is so hot right now. Signals bloggers have covered CAR T cells (here and here), but haven’t given some other exciting immunotherapies their time to shine. I aim to correct that. A normal part of the immune system, checkpoints are a mechanism to...
Comments